Preclinical activity of the rational combination of selumetinib (AZD6244) in combination with vorinostat in KRAS-mutant colorectal cancer models Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Benzimidazoles
  • Colorectal Neoplasms
  • Histone Deacetylase Inhibitors
  • Hydroxamic Acids
  • Mutation
  • Proto-Oncogene Proteins
  • ras Proteins

abstract

  • These data indicate that the rationally based combination of the mitogen-activated protein kinase/extracellular signal-regulated kinase inhibitor, selumetinib, with the HDAC inhibitor vorinostat results in synergistic antiproliferative activity against KRAS-mutant CRC cell lines in vitro. In vivo, the combination showed additive effects that were associated with metabolic changes in phospholipid turnover, but not on FDG-PET, indicating that the former is a more sensitive endpoint of the combination effects.

publication date

  • February 15, 2012

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3876277

Digital Object Identifier (DOI)

  • 10.1158/1078-0432.CCR-11-1507

PubMed ID

  • 22173548

Additional Document Info

start page

  • 1051

end page

  • 62

volume

  • 18

number

  • 4